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Abstract
Here we engineered transgenic Leishmania infantum that express luciferase, the objectives being to more easily monitor in
real time their establishment either in BALB/c mice—the liver and spleen being mainly studied—or in vitro. Whatever
stationary phase L. infantum promastigotes population—wild type or engineered to express luciferase—the parasite burden
was similar in the liver and the spleen at day 30 post the intravenous inoculation of BALB/c mice. Imaging of L. infantum
hosting BALB/C mice provided sensitivity in the range of 20,000 to 40,000 amastigotes/mg tissue, two tissues—liver and
spleen—being monitored. Once sampled and processed ex vivo for their luciferin-dependent bioluminescence the
threshold sensitivity was shown to range from 1,000 to 6,000 amastigotes/mg tissue. This model further proved to be
valuable for in vivo measurement of the efficiency of drugs such as miltefosine and may, therefore, additionally be used to
evaluate vaccine-induced protection.
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Introduction
Leishmania are obligate intracellular dimorphic protozoan para-
sites that cause a broad spectrum of clinical diseases in mammalian
hosts. Visceral leishmaniasis, due to L. infantum, is endemic in the
mediterranean basin (Mediterranean Visceral Leishmaniasis, MVL)
andis a fatal disease,if untreated.To date, noefficient vaccine exists
against human MVL and therapeutic options for managing MVL
are limited with significant toxicity in some cases.
Exploring novel molecules for use as leishmanicidal drugs or
vaccines necessitates experimental models such as in vitro culture of
mouse or human-derived macrophages or laboratory susceptible
mice. The standard method for monitoring infection in the mouse
model is based on the estimation of parasite loads in target organs
such as liver, spleen, or lymph nodes by microscope examination of
touch imprints or smears. Alternatively, limiting culture dilution or
qPCR amplification of parasite DNA is performed [1]. These
techniques are however cumbersome and require large groups of
mice to be euthanized to follow the efficiency of leishmanicidal drugs
or time-course efficacy of vaccines against MVL. To overcome these
drawbacks, a few real time monitoring methods, using reporter genes
encoding GFP or firefly luciferase, have been developed for in vitro
drug screening [2–7] or in vivo individual follow-up of Leishmania
infection inthemousemodel [8–13].Mostinvivostudieshave focused
on dermotropic species. Only a limited number of experiments have
been conducted concerning visceral species (L. donovani and L. chagasi),
which target deep organs [10,13]. In particular, no complete study
using transgenic L. infantum has until now been reported.
In this paper, we have engineered transgenic L. infantum stably
expressing luciferase. We then aimed to assess their usefulness for
monitoring - in vivo and ex vivo - L. infantum biomass overtime in
liver and spleen of BALB/c mice inoculated with a high parasite
dose. Particular attention has been paid to the suitability - in vitro
and in vivo - of recombinant L. infantum-expressing luciferase for
screening the efficiency of leishmanicidal drugs such as miltefosine.
Materials and Methods
Mice and ethics statement
Six to eight week-old female BALB/c mice were purchased
from Charles River (France). Mice were maintained and handled
according to the regulations of the European Union, the French
Ministry of Agriculture and to FELASA (the Federation of
Laboratory Animal Science Associations) recommendations.
Experiments were approved by the ethics committee of the Nice
School of Medicine, France (Protocol number: 2010-45).
Promastigote culture
L. infantum MON-1 (MHOM/FR/94/LPN101), was isolated
from a patient with MVL contracted in the Nice area (South of
www.plosntds.org 1 September 2011 | Volume 5 | Issue 9 | e1323France). L. infantum promastigotes were routinely grown at 26uCi n
M199 medium supplemented with adenosine 0.1 mM, biotin
1 mg/ml, bovine hemin 5 mg/ml, streptomycin 100 mg/ml,
penicillin 100 U/ml, 2 mg/ml biopterin, L-glutamine 2 mM, folic
acid 10 mg/ml and 10% fetal calf serum (culture medium) [14].
Generation of recombinant L. infantum-expressing
reporter genes
L. infantum clones encoding firefly luciferase were generated as
previously described [8]. Briefly, the 1.66 kb coding region of
firefly luciferase was cloned into the Leishmania expression vector
pF4x1.HYG, with marker gene for selection with hygromycin B.
Following linearization by SwaI restriction digest, an insert
containing 18S rRNA flanked with the luciferase gene and
hygromycin, was prepared for integration into the 18S rRNA
locus of the nuclear DNA of L. infantum. L. infantum promastigotes
(0.5610
8), in exponential growth phase, were suspended in 0.5 ml
of cytomix buffer (25 mM HEPES pH 7.5, 0.15 mM
CaCl2,120 mM KCl,10 mM KH2PO4, 2 mM EDTA, 5 mM
MgCl2). Transfections were performed by electroporation (Gene
Pulser X cell System, Biorad) using 3 mg of DNA inserts with the
following conditions: 25 mF, 1600 v, 9 ms in 4 mm cuvette.
Following electroporation, transfected parasites were cultured in
complete culture medium and plated on semi-solid medium
containing 100 mg/ml of hygromycin B. L. infantum colonies were
collected, expanded in culture medium with hygromycin,
aliquoted and frozen in liquid nitrogen in 90% fetal calf serum
with 10% DMSO until use. Before inoculation experiments, a
single promastigote clone termed LUC-parasite was passaged
twice in M199 medium containing hygromycin. Occasionally, to
maintain virulence, the LUC-parasite was injected by intra-
peritoneal (IP) route to BALB/c mice and two months later, spleen
or liver was collected and cultured as a source of promastigotes.
Inoculation with LUC-parasites or wild type parasites in
vivo and quantification of parasite loads
Variable inocula of the stationary phase LUC-parasites or wild
type (WT) promastigotes (ranging from 0.12610
8 to 3610
8
parasites) in stationary phase of growth, were injected by
intravenous (IV) route to groups of 4 of 6–8 week-old female
BALB/c mice. One month later, the animals were euthanized by
CO2 and spleens and livers were collected. Spleen and liver
aliquots were homogenized at 100 mg/ml in PBS containing 1%
Nonidet P40 and a protease inhibitor cocktail (Roche), and
parasite loads were quantified by an ELISA-based method as
previously described [15,16]. For follow-up studies, mice were
infected as above, and at different time-points imaging was
performed. Occasionally, mice were infected by the intraperito-
neal route (IP) with 500610
6 stationary phase LUC-parasites and
regularly imaged.
Bioluminescence imaging of L. infantum infected BALB/c
mice
Mice infected with LUC-parasites were periodically imaged
using the Photon Imager (Biospace Lab, France) system as follows:
mice were administered with luciferin (Caliper life science, France)
at 300 mg/kg by IP route, and within 10 min, the animals were
anesthetized in 5% isoflurane/1L O2.min
21 atmosphere. The
animals were then placed in the imaging chamber of the Photon
Imager and anesthetisis was maintained using 2.0% isoflurane/
0.2 L O2 per mouse min-1 atmosphere. Acquisition of emitted
photons, with a charge-coupled device camera, was monitored
over a 20 min period in previously defined regions of interest
(ROI) that delimited the surface of analysis. To standardize
imaging, and to allow comparison between mice, the images
presented in the figures correspond to an acquisition of 1 min
duration, taken once luminescence plateaued. In some experi-
ments, bioluminescence imaging (BLI) localization of transgenic
luciferase expressing L. infantum amastigotes to mouse liver, spleen
or other sites was confirmed by reimaging mouse after dissection.
In vitro analysis of luminescence activity and quantitation
of parasite loads ex vivo
In vitro luminescence activity was measured using the Luciferase
Assay System E1501 (Promega). To quantify ex vivo parasite
burdens by luminescence, Nonidet P40 extracts of spleen or liver,
prepared as above, were serially diluted with the reporter lysis
buffer. Luminescence was quantified from 10 ml aliquot (1 mg
tissue) using a luminometer (Centro LB 960 Berthold Technolo-
gies, Germany). To compare luciferase activity of promastigote
and amastigote forms, the exponentially growing LUC-promasti-
gote clone, and spleen or liver aliquots from infected mice, were
extracted with NP 40 buffer and parasites number was quantified
by ELISA. Detergent extracts were serially diluted and lumines-
cence activity was analysed as above.
In vitro infection of monocytic cells with luciferase clone
for drug screening
The THP-1 cell line (ATCC TIB-202) was routinely grown in
RPMI 1640 medium containing 10% fetal calf serum and
differentiated overnight at 10
6/ml density with 10 ng/ml of
phorbol myristate acetate (PMA) in 96-well microtiter plate. Wells
were then washed with RPMI and fresh complete medium was
added. PMA-differentiated THP-1 cells were infected with
stationary phase LUC-parasites, at parasite to THP-1 cell ratio
of 10:1, for 3 h at 37uC. Free parasites were aspirated off and the
plate was incubated for 48 h in culture medium for amastigote
transformation. Miltefosine (hexadecylphosphocholine, Sigma)
was added at concentrations ranging from 10
28 to 10
24 M and
within 48 h the plate was washed and the wells were extracted
using 50 ml of reporter lysis buffer. Luminescence activity was
Author Summary
Leishmania infantum/L. chagasi parasites are inoculated in
the skin of mammals by sand flies. Though most often
these L. infantum-mammal interactions are asymptomatic,
they can proceed, in some individuals, to a systemic
disease known as visceral leishmaniasis. If left untreated
this disease is fatal. The lack of protective or curative
vaccines and the limited number of parasite-targeting
drugs were incentive to set up experimental conditions
that could allow easy monitoring of the fluctuation of the
population size of parasites in living laboratory animals.
Thus, in the present report, we depict two distinct readout
assays that rely on a population of L. infantum we
genetically engineered for stably expressing the firefly
luciferase gene. These transgenic parasites were either
inoculated to BALB/c mice or added to a culture of
monocytic cells. Post intravenous inoculation, BALB/c mice
were imaged over time, with special attention being given
to the liver and the spleen. The sensitivity of this technique
ranged from 20,000 to 40,000 parasites/mg of tissue and
from 1,000 to 6,000 parasites/mg tissue, for in vivo and ex
vivo measurements, respectively. Though preliminary, the
data, relying on monocytic cells, are promising for further
in vitro screening of small compound libraries.
Transgenic Leishmania infantum as a Versatile Tool
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evaluated using Trypan blue exclusion.
Results
Infectivity of luciferase L. infantum and in vivo and ex vivo
evaluation of parasite burdens using bioluminescence
In order to assess the infectivity of the L. infantum luciferase
parasites (LUC-parasite), as well as the usefulness of biolumines-
cence for the monitoring of parasite proliferation in target organs,
BALB/c mice were inoculated by IV route with various inocula of
the stationary phase LUC-parasites or WT parasites. One month
following inoculation, when generally both liver and spleen are
infected, mice were imaged and sacrificed. Detergent extracts from
liver or spleen were prepared for parasite quantification by ELISA
or bioluminescence analysis ex vivo. Figure 1A shows that mice
inoculated with increasing numbers of the LUC-parasite or WT
parasites exhibited increasing and similar spleen and liver parasite
burdens. This indicates that the selected LUC-parasite exhibits an
infectivity identical to that of WT parasites (Fig. 1A). Identical
results were obtained with another LUC-parasite (data not shown).
In order to evaluate the threshold sensitivity of BLI, LUC-parasite
infected mice were imaged and the luminescence (expressed as
photons/s/cm
2) present in a ROI corresponding to liver or spleen
was recorded. Despite variable infection levels in mice infected
with the same parasite dose, imaging of bioluminescence signals
confirmed the parasite dose-dependency of the infection measured
by ELISA (Fig. 1A). Luminescence measured in the ROI and
express as photon/s/cm
2, was directly proportional to parasite
density, and the generated regression curves were used for
estimating the threshold sensitivity of BLI for both organs
(Fig. 1B). The threshold sensitivity of BLI was calculated as
luminescence three times stronger than background luminescence
of naı ¨ve mice, which exhibit the same background values as non-
bioluminescent parasite infected mice. In our hands, threshold
sensitivity was around 20,000 and 40,000 parasites per mg spleen
and liver, respectively (above the grey zone of Fig. 1C).
We next assessed the possibility of measuring parasite loads by
ex vivo analysis of organ luminescence. L. infantum parasites are
present in the host as intracellular amastigotes, and are the form
targeted by drugs and vaccines. As these amastigote forms
generally display a lower metabolic activity than exponentially
growing promastigotes we compared in vitro luciferase activity of
both parasite forms. Figure 1D shows the dose-response curves
drawn from luciferase parasites under promastigote or spleen and
liver amastigote forms. As expected, luciferase activity of
amastigotes was notably lower than that of exponentially growing
promastigotes with threshold sensitivities (calculated as twice the
background value) at around 10, 1,000 and 6,000 parasites for
metacyclic promastigotes, spleen and liver amastigotes, respec-
tively (Fig. 1D). The specificity of ex vivo analysis was confirmed by
the lack of luminescence activity of equal numbers of spleen and
liver WT amastigotes. Analysis of luminescence ex vivo thus
facilitates a rapid and simple mean for quantitating parasite
burdens in mouse organs provided a relatively high infection level
is present. Finally, parasite density of samples taken from 36 livers
or spleens were analysed both by luminescence analysis and
ELISA. Strong correlation between the two methods verified the
reliability of the bioluminescence assay (Fig. 1E).
Monitoring of L. infantum infection and in vivo drug
screening by bioluminescence imaging
BALB/c mice inoculated with L. infantum WT parasites
generally display a liver infection episode, which peaks 1–2
months post inoculation and is partially self-resolved because of
granuloma formation [17]. Partial liver clearance is followed by
progressive and chronic spleen infection with a concomitant
destruction of spleen architecture [17]. We used this model of
infection to assess the usefulness of bioluminescence to follow this
process. For this, BALB/c mice were intravenously infected with
3610
8 and 1610
8 stationary phase promastigotes of the LUC-
parasite, and at different time-points, the spread of infection was
recorded following IP injection of the luciferin substrate. Time-
course infection followed by BLI (Fig. 2A) revealed the classical
transitory hepatic episode (day 14) followed by parasite spleen
colonization (day 40) (Fig. 2A). Of note, in the two heavily infected
mice (3610
8), inguinal and mediastinal lymph nodes were
persistently bioluminescent (Fig. 2A). Conversely, bone marrow
parasite localisation could not be evidenced.
Next, in order to validate this technique for drug screening
purposes, either in vivo or in vitro, we conducted experiments using
miltefosine as a leishmanicidal drug. For in vivo testing, infected
mice were treated with miltefosine for 5 days (1 mg per mouse per
day) and imaged 2 days later. Figure 2A shows that parasite
decrease can be readily detected by BLI imaging in vivo,a s
luminescence was undetectable in spleen or lymph nodes following
5 days of treatment (Fig. 2A). This reduction was seen regardless of
the infection level before treatment and was confirmed following
dissection of mice and measurement of spleen burdens (Fig. 2A).
Therefore, parasite clearing by miltefosine in spleen was
accompanied by the disappearance of luminescence.
Similarly, luminescence was used in vitro to evaluate the efficacy
of miltefosine on intracellular amastigotes. PMA-differentiated
THP-1 cells were infected with metacyclic LUC-parasites and
within 48 h, a time sufficient for amastigote transformation (data
not shown), miltefosine was added. 48 h later, THP-1 cells were
lysed and luciferase activity was quantified. Figure 2B shows the
drug-concentration dependency of amastigote killing by miltefo-
sine (Fig. 2B). The IC 50 (1.5 mM) was identical to that previously
reported [18]. Using this method, drug-concentration dependency
of amastigotes killing could be measured (Fig. 2B). This protocol
may therefore provide a high throughput method for screening
drugs.
Demonstration of a new potential site of parasite
proliferation by bioluminescence imaging
Preliminary experiments showed that BALB/c mice infected via
the IP route with 5610
8 LUC-parasites displayed hepatic and
spleen infection episodes similar to that observed following IV
challenge (data not shown). However, infection levels in target
organs were generally lower than that observed following infection
by the IV route. Nevertheless, by day 40 post inoculation,
peritoneum bioluminescence, clearly distinct from spleen biolu-
minescence (Fig. 3A, 3B), was detectable in nearly all infected mice
and was still observable 3 months post inoculation (data not
shown). Dissection of mice showed that peritoneal bioluminescent
parasites localized to a mass of adipose tissue located above the
intestine (Fig. 3C, 3D). Interestingly, BLI and quantitation of
amastigotes in adipose tissue indicated that compared to spleen, 20
times more photons per parasite could be recovered from
peritoneum amastigotes. Therefore, BLI can be useful to
demonstrate unexpected sites of parasite proliferation.
Discussion
The BALB/c mouse model has been widely used for drug
screening and vaccine trials, since therapeutic effects of drugs or
vaccine-induced protection are evaluated keeping the contextual
Transgenic Leishmania infantum as a Versatile Tool
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loads at different time-points in target organs necessitates
euthanizing and dissecting animal groups, thus limiting longitu-
dinal studies devoted to the therapy of MVL. In addition, parasite
loads are extrapolated from parasite counts obtained on a limited
sample size, which is not always representative of the burden
occurring in the organ. Finally, spread of parasites to an
unexpected site of infection may be missed because the infected
tissue is not harvested or analysed.
Recently, the possibility of labelling invasive microorganisms
with reporter genes, such as firefly luciferase has provided, the
ability to trace the infection dissemination at the tissue/organ level
by BLI in animal models. BLI potentially presents many
advantages over conventional methods of infection monitoring.
BLI technology allows detection of only live, metabolically active
cells and because of its non-destructive and non-invasive nature it
can be performed repeatedly. BLI thus permits each animal to be
used as its own control over time, overcoming the problem of
animal-animal variations. Finally, as already reported, by using
this technique new microorganism localization can be evidenced
[19].
We report here the generation of recombinant luciferase L.
infantum parasites and their use in tracing parasite dissemination in
vitro and in vivo. Our results show that luciferase transfected
parasites are suitable for both in vitro and in vivo studies. While light
emission of the amastigote form was reduced as compared to that
Figure 1. Infectivity of LUC-parasites and sensitivity of bioluminescence in vivo and ex vivo. A. Infectivity of Luc-parasites as compared to
L. infantum WT parasites. Both luciferase transgenic and wild type L. infantum stationary phase promastigotes establish themselves in BALB/c mice.
Groups of 4 BALB/c mice were given either 0.12610
8 to 3610
8 stationary phase luciferase-transgenic or wild type L. infantum. One month later, mice
were imaged, the bioluminescence being recorded before their sacrifice. L. infantum burdens were estimated by ELISA in the liver and the spleen.
Burdens were calculated as parasite/mg organ x organ weight (in mg). Data representative of three experiments are presented as box whisker plots.
For statistical analysis Man Whitney Wilcoxon test was performed and did not show any significant difference between parasite loads of mice
inoculated with WT or luciferase parasites; ns= not-significant. B. Bioimaging of BALB/c mice one month post the IV inoculation of luciferase transgenic
L. infantum. Mice inoculated with LUC-parasite and with parasite loads depicted in figure 1A, were given luciferin via IP. The photon emission was
recorded once the anesthetized mice were deposited in the imaging chamber of the Photon Imager. Red zones are ROIs that delineate the liver or
spleen. C. Sensitivity of BLI. Luminescence (photon/s/cm
2) was recorded in ROIs corresponding to liver and spleen of the 11 mice infected with LUC-
parasites depicted in figure 1A. Luminescence recorded in ROIs was plotted versus parasite density measured by ELISA as described in figure 1A to
generate regression curves. The threshold sensitively of BLI calculated as three times luminescence of naı ¨ve mice (indicated by the gray zone) was
20,000 to 40,000 parasites/mg for spleen and liver respectively. D. Ex-vivo quantification of parasite loads by bioluminescence. Luminescence of equal
numbers of the LUC-parasite under exponentially growing promastigote form or liver and spleen amastigotes was analyzed using a luminometer.
Equal numbers of liver and spleen amastigotes from mice infected with WT promastigotes were used as specificity control. Sensitivity of ex vivo
analysis of parasite density by bioluminescence (1,000 to 6,000 amastigotes/mg for spleen and liver respectively) was calculated as parasite numbers
corresponding to twice luminescence background values. E. Accuracy of ex vivo bioluminescence analysis for estimation of parasite density. Liver and
spleen samples from 18 IV infected BALB/c mice were detergent extracted and assayed both by ELISA and bioluminescence. Values generated by
both techniques were plotted to generate regression curves.
doi:10.1371/journal.pntd.0001323.g001
Transgenic Leishmania infantum as a Versatile Tool
www.plosntds.org 4 September 2011 | Volume 5 | Issue 9 | e1323Transgenic Leishmania infantum as a Versatile Tool
www.plosntds.org 5 September 2011 | Volume 5 | Issue 9 | e1323of extracellular promastigotes it was sufficient to provide an
accurate and rapid estimation of parasite loads ex vivo with a
sensitivity of around 1 to 6,000 amastigotes/mg tissue, which is
sufficient for most applications. Importantly, luciferase parasite
clones proved to be also useful tools to measure drug efficacy of
miltefosine in vitro and in vivo at the amastigote stage. Luminescent
L. infantum parasites may thus represent a high throughput method
for leishmanicidal drug testing on different target organs in the
context of the whole body.
BLI of BALB/c mice infected with luciferase clones showed that
in our conditions, the threshold sensitivity of parasite burdens was
around 20610
3 to 40610
3 parasites/mg for spleen and liver. This
Figure 3. Localization of bioluminescent parasites in intra-abdominal mesenteric fat in BALB/c mice infected by IP route. 4 Mice were
infected with 5610
8 of LUC-parasites by IP route. Infection was monitored by BLI. On day 40 post infection (Fig 3A), mice showed intraperitoneal
parasites localisation by BLI. One representative mouse (Fig 3B) was dissected and the adipose tissue localization detected by bioluminescence was
verified in situ (Fig 3C) and after removing the adipose tissue and reimaging (Fig 3D). The illustrations are representative of at least three different
experiments.
doi:10.1371/journal.pntd.0001323.g003
Figure 2. Monitoring of L. infantum infection using BLI and application for leishmanicidal drug screening. A. Follow up of infection by BLI
and drug screening in vivo. Groups of 2 BALB/c mice were IV infected with 1610
8 or 3610
8 of stationary phase LUC-parasites and animals were
imaged at the indicated times. BLI of mice shows the typical liver infection followed by spleen parasite colonization. By day 40, 3 mice with different
levels of spleen infection were treated with miltefosine during 5 days (+) and reimaged 2 days later. Miltefosine efficacy was illustrated by the loss of
luminescence signal compared to a control non treated mouse. Efficacy was confirmed by parasite counts (number of parasites/mg organ) measured
by ELISA following dissection (indicated below each mouse tested). The illustration is representative of three different experiments. B. In vitro drug
screening. PMA-differentiated THP-1 cells in 96 well microplates were incubated for 3 h with stationary phase LUC-parasites at a parasite-to-THP-1 cell
ratio of 10:1. After 48 h incubation, miltefosine at concentrations ranging from 10
24 to 10
28 M were delivered. 48 h later, the plate was washed and
wells were lysed with 50 ml of reporter lysis buffer. 20 ml of supernatant was assayed for luminescence activity and showed a clear negative
correlation between the drug concentration and luminescence of parasites. IC 50 was measured at 1.5 mM. Cell viability measured by trypan blue
exclusion was 83% and 96% for miltefosine concentration of 100 mM and 10 mM, respectively. The dose dependency of miltefosin efficacy on parasite
killing is representative of 3 different experiments.
doi:10.1371/journal.pntd.0001323.g002
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loads. In our hands, these infection levels could be easily reached
by IV route using high parasite inoculum not enriched in
mammal-invasive metacyclic promastigotes. Following IP parasite
delivery we noticed a new site of parasite development located in
the peritoneum. The demonstration of this unexpected localiza-
tion, which has not been observed in mice infected by IP with L.
donovani [8], suggests that this localisation may be species specific.
The high photon emission observed in adipose tissue (numbers of
photon/parasite) as compared to spleen emphasizes the fact that,
due to different local environments, luminescence emitted by
different organs cannot be compared but for a given organ it
reflects differences in parasite loads. Absorption and scattering of
light by overlaying tissues may account for this difference though it
is likely that the delivery of luciferin directly into the peritoneum
facilitated better photon emission from the peritoneum. Collec-
tively we demonstrate that BLI represents a versatile tool for drug
screening in vitro or in vivo as well as for assessing the potential
protectivity of vaccine preparations. More sensitive cameras and/
or luciferase with improved catalytic activity or a higher vector
expression [20], will undoubtedly improve the performance and
ability of BLI of L. infantum.
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